Pangea Bio

Pangea Bio is a clinical-stage biotechnology company developing small molecule therapeutics for neurological and neuropsychiatric disorders.

Its proprietary AI platform screens natural and plant-derived chemical space, integrating ethnobotanical data with machine learning to identify novel CNS drug candidates with established human tolerability profiles.

Its lead asset OT-003, a TrkB receptor agonist, has received Clinical Trial Authorisation and is being advanced across multiple neurodegenerative and neuropsychiatric indications. AI discovery services are also offered to external partners.